Pharmacokinetics of trans-resveratrol following repeated administration in healthy elderly and young subjects

Journal of Clinical Pharmacology

Volumn 49, Issue 12, 2009, Pages 1477-1482

  Nunes, Teresa ^a   Almeida, Luis ^a,b,c   Rocha, José Francisco ^a   Falcão, Amílcar ^d   Fernandes Lopes, Carlos ^a   Loureiro, Ana I ^a   Wright, Lyndon ^a   Vaz Da Silva, M ^a,b   Soares Da Silva, Patrício ^a,c  

^a DEPARTMENT OF RESEARCH AND DEVELOPMENT   (Portugal)

^b University of Porto   (Portugal)

^c UNIVERSITY OF AVEIRO   (Portugal)

^d Biocant   (Portugal)

Author keywords

Age effect; Bioavailability; Gender effect; Pharmacokinetics; Trans resveratrol

Indexed keywords

RESVERATROL;

ADULT; AGE; AGED; AREA UNDER THE CURVE; ARTICLE; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; SEX DIFFERENCE; SINGLE DRUG DOSE;

ADULT; AGED; AGING; ANTIPARKINSON AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LEVODOPA; MALE; STILBENES; YOUNG ADULT;

EID: 71449113221     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009339191     Document Type: Article

References (20)

1. de la Lastra CA, Villegas I. Resveratrol as an anti-inflammatory and anti-aging agent: mechanisms and clinical implications. Mol Nutr Food Res. 2005 ; 49 (5). 405-430.
2. Fremont L. Biological effects of resveratrol. Life Sci. 2000 ; 66 (8). 663-673.
3. Bhat KPL, Kosmeder JW II, Pezzuto JM Biological effects of resveratrol. Antioxid Redox Signal. 2001 ; 3 (6). 1041-1064.
4. Kopp P. Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conundrum of the French paradox? Eur J Endocrinol. 1998 ; 138 (6). 619-620.
5. Zhuang H., Kim YS, Koehler RC, Dore S. Potential mechanism by which resveratrol, a red wine constituent, protects neurons. Ann N Y Acad Sci. 2003 ; 993: 276-286.
6. Bruno R., Ghisolfi L., Priulla M., Nicolin A., Bertelli A. Wine and tumors: study of resveratrol. Drugs Exp Clin Res. 2003 ; 29 (5-6). 257-261.
7. Aziz MH, Kumar R., Ahmad N. Cancer prevention by resveratrol: in vitro and in vivo studies and the underlying mechanisms. Int J Oncol. 2003 ; 23: 17-28.
8. Cal C., Garban H., Jazirehi A., Yeh C., Mizutani Y., Bonavida B. Resveratrol and cancer: chemoprevention, apoptosis, and chemoimmunosensitizing activities. Curr Med Chem Anticancer Agents. 2003 ; 3 (2). 77-93.
9. Delmas D., Lancon A., Colin D., Jannin B., Latruffe N. Resveratrol as a chemopreventive agent: a promising molecule for fighting cancer. Curr Drug Targets. 2006 ; 7 (4). 423-442.
10. Anekonda TS Resveratrol-a boon for treating Alzheimers disease ? Brain Res Rev. 2006 ; 52 (2). 316-326.
11. Kumar A., Kaundal RK, Iyer S., Sharma SS Effects of resveratrol on nerve functions, oxidative stress and DNA fragmentation in experimental diabetic neuropathy. Life Sci. 2007 ; 80 (13). 1236-1244.
12. Palma PN, Bonifacio MJ, Almeida L., Soares-da-Silva P. Restoring dopamine levels. In: Smith HJ, Simons C, Sewell RDE, eds. Protein Misfolding in Neurodegenerative Diseases. Boca Raton, FL: CRC Press ; 2008: 415-445.
13. Soares-da-Silva P. Patent WO 01/068065 A3. Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinsons disease. World Intellectual Property Organization ; 2001.
14. Nutt JG Pharmacokinetics and pharmacodynamics of levodopa. Mov Disord. 2008 ; 23 (suppl 3). S580 - S584.
15. Chow S-C., Wang H. On sample size calculation in bioequivalence trials. J Pharmacokinet Pharmacodyn. 2001 ; 28 (2). 155-169
16. Walle T., Hsieh F., DeLegge MH, Oatis JE Jr, Walle UK High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos. 2004 ; 32 (12). 1377-1382.
17. Wenzel E., Somoza V. Metabolism and bioavailability of trans-resveratrol. Mol Nutr Food Res. 2005 ; 49 (5). 472-481.
18. Boocock DJ, Faust GE, Patel KR, et al. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev. 2007 ; 16 (6). 1246-1252.
19. Almeida L., Vaz-da-Silva M., Falcao A., et al. Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol Nutr Food Res. 2009. In press.
20. Wang LX, Heredia A., Song H., et al. Resveratrol glucuronides as the metabolites of resveratrol in humans: characterization, synthesis, and anti-HIV activity. J Pharm Sci. 2004 ; 93 (10). 2448-2457.